

University of Groningen

Aspects of palliative chemotherapy for lung cancer

Smit, Egbert Frederik

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:

1990

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Smit, E. F. (1990). Aspects of palliative chemotherapy for lung cancer s.n.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Aspects of palliative chemotherapy for lung cancer

RIJKSUNIVERSITEIT GRONINGEN

**Aspects of palliative chemotherapy
for lung cancer**

Proefschrift

ter verkrijging van het doctoraat in de Geneeskunde
aan de Rijksuniversiteit Groningen
op gezag van de Rector Magnificus Dr. L.J. Engels
in het openbaar te verdedigen op woensdag 3 oktober 1990
des namiddags te 4.00 uur

door

Egbert Frederik Smit

geboren op 24 mei 1961 te Winschoten

Promotores : Prof. Dr. G.H. Koëter
Prof. Dr. G.K. van der Hem

Referenten : Dr. E.G.E. de Vries
Dr. P.E. Postmus
Dr. N.H. Mulder

The printing costs were supported by kind contributions of the Stichting Werkgroep
Interne Oncologie and Bristol-Myers.

ISBN 90-9003704-7

Zetwerk en lay-out: COMPUTEKST grafische tekstverwerking, Groningen
Druk: Dijkhuizen Van Zanten bv, Groningen

CONTENTS

Introduction	1
Chapter 1. Small cell lung cancer in the elderly; factors influencing treatment outcome. A review. Lung cancer, 5: 82-91,1989.	5
Chapter 2. Phase II study of oral etoposide in elderly patients with small cell lung cancer. Thorax 44: 631-633,1989.	19
Chapter 3. A Phase I study of oral teniposide. Seminars in Oncology, in press.	23
Chapter 4. Phase II study of teniposide for CNS metastases of small cell lung cancer. Seminars in Oncology, in press.	31
Chapter 5. Acute and cumulative effects of carboplatin on renal function. Br. J. Cancer, 60: 56-60,1989.	39
Chapter 5 ^a Carboplatin and renal function. Ann. Int. Med.: 110,1034,1989.	49
Chapter 6. A Phase II study of carboplatin and vincristine in previously treated patients with small cell lung cancer. Cancer Chemotherapy and Pharmacology, 25: 202-204,1989.	51
Chapter 7. A Phase II study of carboplatin and vincristine in non small cell lung cancer. Submitted.	57
Chapter 8. Continuous infusion of carboplatin on a 21 day schedule - a Phase I and pharmacokinetic study. J. Clin. Oncol. - in press.	63
Chapter 9. Phase I study of 21 days continuous infusion of vindesine. Br. J. Cancer, 59:471-472,1989.	81

Chapter 10.	In vitro response of human small cell lung cancer cell lines to chemotherapeutic drugs; no correlation with clinical data. Submitted.	85
Chapter 11.	Limitations of the fast green assay for chemosensitivity testing in human lung cancer. Submitted.	99
Chapter 12.	Summary and conclusions.	109
Chapter 13.	Samenvatting en conclusies.	113